T1	Participants 26 92	pancreatic cancer with epidermal growth factor receptor mutations:
T2	Participants 432 579	Eighty-eight chemotherapy-na√Øve metastatic pancreatic cancer patients were randomized for treatment with gemcitabine or gemcitabine plus erlotinib
T3	Participants 1176 1244	in patients with EGFR mutations than in those without EGFR mutations
T4	Participants 1400 1484	treating metastatic pancreatic cancer patients, especially those with EGFR mutations
